Chronic Kidney Disease-related Renal Anemia
Conditions
Interventions
ESAs Group:None
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years, any gender; 2. CKD stages 3–5, with estimated glomerular filtration rate (eGFR) assessed during the screening period (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula), and not receiving renal replacement therapy; 3. HB measurement value 70-100 g/L; 4. Voluntarily sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1.he number of follow-up visits is less than three times. 2.Known intolerance to ESAs, injectable iron preparations, and polyethylene glycol molecules; 3.Known to have hematologic disorders (including congenital and acquired conditions such as thalassemia, Fanconi anemia, aplastic anemia, myelodysplastic syndrome, hemolytic anemia, and coagulation dysfunction) or other etiologies leading to anemia besides CKD (such as gastrointestinal bleeding, hookworm disease, or celiac disease). 4.Exclude patients with congenital heart disease, severe valvular disease, myocardial disease, and pericardial disease. 5.Researchers consider subjects with any other factors deemed unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVMI Modification (CMR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline in NT-proBNP, CMR, and other indicators;Change in mean HB points from baseline after baseline;The proportion of subjects whose HB average is maintained at 100 g/L <= HB <= 120 g/L and the medication dosage;Change from baseline in the mean values of TSAT, SF, and hepcidin;Mean change from baseline in hs-CRP and IL-6 at each time point;Adverse event;Time to death or MACE during follow-up; | — |
Countries
China
Contacts
Public ContactMing Fang
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed